Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clesrovimab
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
Clesrovimab (MK-1654, also known as Enflonsia) is an extended half-life, fully human IgG1 monoclonal antibody developed by Merck for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It targets site IV of the RSV fusion (F) protein, acting as a fusion inhibitor to prevent viral entry into host cells. Clesrovimab is engineered with half-life extending mutations (YTE) in the Fc region to provide durable protection throughout a typical RSV season with a single, weight-independent dose. It was approved by the US FDA in June 2025 and by the European Commission in April 2026, and is under regulatory review in other regions, including Japan (where it is known as cresrovimab).
- Brand names
- Enflonsia
- Other names
- clesrovimab-cforcresrolimabcresrovimab
02
Targets
RSV F (Respiratory syncytial virus fusion protein)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on clesrovimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clesrovimab.